Drug Approval | November 13, 2024
EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
US Generics grew 5% to Rs. 467 Crores for the quarter
Subscribe To Our Newsletter & Stay Updated
